

Hikma Ventures participates in a \$19 million round for Click Therapeutics

London, 4 October 2018 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) announces that its venture capital arm, Hikma International Ventures and Development LLC (Exempt) "Hikma Ventures" has participated in a \$19 million round of financing for Click Therapeutics alongside Sanofi Ventures, the Cambridge-based venture capital arm of French drugmaker Sanofi (NYSE: SNY) who led the round.

New York-based Click Therapeutics (Click), a leading Software as a Medical Device (SaMD) company, develops mobile apps intended to be prescribed by doctors to treat medical conditions, either on their own or in tandem with drugs or other standard treatments. The six-year-old company is working on software that delivers cognitive and neurobehavioral interventions, aimed at treating depression, insomnia, acute coronary syndrome, and chronic pain. Click plans to seek FDA clearance to market those products as class 2 medical devices with disease-specific treatment claims. The company's lead experimental product, designed to treat major depressive disorder in adults, is entering a randomized, controlled, phase 3 trial.

Lana Ghanem, Managing Director of Hikma Ventures, said, "The field of digital medicine has been advancing at a significant pace; we are excited to be part of Click's journey as the use of digital therapies continues to gain momentum. Click Therapeutics' technology and platform are designed to deliver clinically-proven treatments that demonstrate significant benefits to patients. We are looking forward to working with the team and co-investors to help advance the development of their pipeline of prescription digital treatments and to commercialize their programs."

"We at Click Therapeutics are excited for Hikma Ventures to join us, alongside Sanofi Ventures and Magellan Health, in bringing digital therapeutics into mainstream healthcare," commented David Benshoof Klein, Co-founder and CEO of Click. "We continue to see tremendous progress in the field and have made great strides in advancing our own proprietary platform and pipeline. This additional funding will help us to continue to develop and validate our programs across multiple indications."

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Lana Ghanem, Managing Director, Hikma Ventures
Susan Ringdal, VP Corporate Strategy and Investor Relations

+962(0)6 5802900/ +962 79 8579391
+44 (0)20 7399 2760/ +44 7776 477050

FTI Consulting

Ben Atwell/ Brett Pollard

+44 (0)20 3727 1000



About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world.

For more information, please visit www.hikma.com.

About Hikma Ventures

Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.

For more information, visit www.hikmaventures.com

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Click's lead prescription program is entering a multi-centred, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

For more information, visit www.clicktherapeutics.com